JP2008531755A - 二重画像化および放射線化学療法のためのコンジュゲート：組成物、製造および適応 - Google Patents

二重画像化および放射線化学療法のためのコンジュゲート：組成物、製造および適応 Download PDF

Info

Publication number
JP2008531755A
JP2008531755A JP2007550450A JP2007550450A JP2008531755A JP 2008531755 A JP2008531755 A JP 2008531755A JP 2007550450 A JP2007550450 A JP 2007550450A JP 2007550450 A JP2007550450 A JP 2007550450A JP 2008531755 A JP2008531755 A JP 2008531755A
Authority
JP
Japan
Prior art keywords
compound
moiety
imaging
cancer
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007550450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531755A5 (enExample
Inventor
デイビッド ジェイ． ヤン，
ドンファン ユー，
ミトゥ チャンダ，
アリ アズダリニア，
チャンソク オー，
イー． エドマンド キム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2008531755A publication Critical patent/JP2008531755A/ja
Publication of JP2008531755A5 publication Critical patent/JP2008531755A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007550450A 2005-01-05 2006-01-05 二重画像化および放射線化学療法のためのコンジュゲート：組成物、製造および適応 Pending JP2008531755A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64155905P 2005-01-05 2005-01-05
PCT/US2006/000269 WO2006074272A2 (en) 2005-01-05 2006-01-05 Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications

Publications (2)

Publication Number Publication Date
JP2008531755A true JP2008531755A (ja) 2008-08-14
JP2008531755A5 JP2008531755A5 (enExample) 2009-08-20

Family

ID=36648161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007550450A Pending JP2008531755A (ja) 2005-01-05 2006-01-05 二重画像化および放射線化学療法のためのコンジュゲート：組成物、製造および適応

Country Status (11)

Country Link
US (2) US8147805B2 (enExample)
EP (1) EP1846042A2 (enExample)
JP (1) JP2008531755A (enExample)
KR (1) KR101313712B1 (enExample)
CN (1) CN101137398B (enExample)
AU (2) AU2006204045B2 (enExample)
BR (1) BRPI0606395A2 (enExample)
CA (1) CA2593256A1 (enExample)
IL (1) IL184415A0 (enExample)
NO (1) NO20074025L (enExample)
WO (1) WO2006074272A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011063572A (ja) * 2009-09-18 2011-03-31 Kyushu Univ 診断用造影剤
JP2014522808A (ja) * 2011-06-17 2014-09-08 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 二官能性ホスホネートキレート剤
JP2015512408A (ja) * 2012-03-26 2015-04-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 画像化および治療のためのエチレンジシステイン−糖接合体の効率的な合成
JP2022544836A (ja) * 2019-08-19 2022-10-21 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド Ｍ２マクロファージおよび骨髄系由来サプレッサー細胞を除去するための組成物ならびに関連する方法
JP2023553494A (ja) * 2020-12-28 2023-12-21 ボストン サイエンティフィック サイムド，インコーポレイテッド 改善された放射線造影特性を有する多糖

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
CN101979095A (zh) 2001-05-02 2011-02-23 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
WO2004110250A2 (en) 2003-05-30 2004-12-23 Purdue Research Foundation Diagnostic method for atherosclerosis
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
ITMI20040928A1 (it) 2004-05-07 2004-08-07 Uni Di Bologna Dipartiment O D Procedura per la preparazione di coniugati della doxorubicina con l'albumina umana lattosaminata
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
WO2006084382A1 (en) 2005-02-11 2006-08-17 University Health Network Compositions and methods for multimodal imaging
US9820986B2 (en) * 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
ITMI20051743A1 (it) * 2005-09-20 2007-03-21 Uni Di Bologna Dipartimento Di Patologia Spa Uso di coniugati della doxorubicina con albumina lattosaminata
US8795633B2 (en) * 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
WO2007126730A1 (en) * 2006-03-29 2007-11-08 Isotherapeautics Group Llc Radionuclide therapy for urinary bladder cancer
BRPI0621580B8 (pt) * 2006-04-19 2021-05-25 Univ Texas composto derivado de n4 e kit compreendendo o referido composto e um agente redutor
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
JP2010509570A (ja) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
WO2008064040A2 (en) * 2006-11-22 2008-05-29 The Board Of Regents Of The University Of Texas System Methods and compositions using chelator-antibody conjugates
US8586595B2 (en) * 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
MX340566B (es) * 2007-03-27 2016-07-14 Radiomedix Inc Composiciones para formacion de imagen objetivo y terapia.
WO2008148001A2 (en) * 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US20120277409A1 (en) * 2007-06-04 2012-11-01 Board Of Regents, The University Of Texas System Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy
GB0725070D0 (en) * 2007-12-21 2008-01-30 Iopharma Technologies Ab Product
DE102008045937B4 (de) * 2008-04-11 2017-01-26 Johannes-Gutenberg-Universität Mainz Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons
US20090264753A1 (en) * 2008-04-22 2009-10-22 General Electric Company Method & system for multi-modality imaging of sequentially obtained pseudo-steady state data
US9061077B2 (en) * 2008-05-05 2015-06-23 Emory University Methods of determining renal function using technetium-99m tricarbonyl-nitrilotriacetic acid
RU2498278C2 (ru) * 2008-07-09 2013-11-10 Конинклейке Филипс Электроникс Н.В. Физиологический фармакокинетический анализ для комбинированной молекулярной магнитно-резонансной томографии и динамической позитронно-эмиссионной томографии
EP2419120A4 (en) * 2009-04-08 2016-01-06 Univ California HUMAN PROTEIN CONCERNS WITH CONTROLLED SERUM PHARMACOKINETICS
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
US8547533B2 (en) 2009-12-28 2013-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composite probes and use thereof in super resolution methods
KR101395085B1 (ko) * 2010-06-11 2014-05-21 국립암센터 종양 및 감시림프절에 특이적인 방사성동위원소 표지된 엽산 결합 인혈청 알부민
CN102218150B (zh) * 2010-08-17 2013-01-30 扬州大学 肝靶向纳米Fe3O4MRI造影剂及制备方法
CN102398026B (zh) * 2010-09-10 2013-10-23 聚和国际股份有限公司 甲壳素修饰的纳米金粒子及其制造方法
CN102558291B (zh) * 2010-12-17 2014-03-12 北京大学人民医院 一种双模分子影像探针
PL2721045T3 (pl) 2011-06-20 2017-11-30 Radiomedix Inc. Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
WO2013086207A1 (en) * 2011-12-06 2013-06-13 The Ohio State University Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
US9675715B2 (en) 2012-07-20 2017-06-13 Canon Kabushiki Kaisha Contrast agent for photoacoustic imaging
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
US9828444B2 (en) * 2012-12-12 2017-11-28 Solvay Specialty Polymers Italy S.P.A. Fluorinated chitosan derivatives
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9850183B2 (en) 2014-06-27 2017-12-26 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
BE1021191B1 (fr) 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
US11027030B2 (en) 2014-08-29 2021-06-08 Anmi S.A. Kit for radiolabelling
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
EP3242688B1 (en) 2015-01-09 2020-01-29 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
US10905783B2 (en) 2015-11-27 2021-02-02 Michal RIVLIN Glucosamine and derivatives thereof in imaging
CN108761078A (zh) * 2018-05-19 2018-11-06 复旦大学 胰腺癌基底微绒毛的检测方法和应用
IL271681A (en) 2018-07-18 2020-01-30 Vyripharm Entpr Llc Systems and methods for integrated and comprehensive management of cannabis products
KR20200047321A (ko) 2018-10-26 2020-05-07 전남대학교병원 체내위치확인을 위한 풍선확장조성물 및 시스템
CN110563859B (zh) * 2019-09-19 2021-07-23 湖北医药学院 抗肝癌药物亚硒酸酯化壳聚糖铜的一锅合成法及应用
CN110981940A (zh) * 2019-11-08 2020-04-10 复旦大学附属肿瘤医院 一种pd-l1结合剂、金属配合物及其使用方法和用途
DE102019135564B4 (de) * 2019-12-20 2022-05-19 Johannes-Gutenberg-Universität Mainz Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
US20220305146A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Radiopharmaceutical compositions and methods for infectious disease diagnosis and therapy
WO2023201377A2 (en) * 2022-04-15 2023-10-19 The General Hospital Corporation Scission-enhanced nuclear imaging and treatment
CN116655928B (zh) * 2023-04-18 2025-08-29 扬州大学 一种基于半胱氨酸的超分子手性光热剂及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003480A1 (en) * 1990-08-17 1992-03-05 Drug Delivery System Institute, Ltd. N-acetylcarboxymethylchitosan derivative and production thereof
JPH0597712A (ja) * 1991-10-04 1993-04-20 Nippon Mejifuijitsukusu Kk 診断用造影剤
WO1997025979A1 (en) * 1996-01-18 1997-07-24 Perio Products Ltd. Gastrointestinal drug delivery system
WO1999018938A1 (en) * 1997-10-09 1999-04-22 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
WO1999020316A1 (en) * 1997-10-20 1999-04-29 Board Of Regents, The University Of Texas System Single photon-emitting radiotraces and methods for their use
WO2000027889A1 (en) * 1998-11-10 2000-05-18 Netech Inc. Functional chitosan derivative
WO2002087498A2 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
WO2003035031A1 (en) * 2001-10-19 2003-05-01 Baxter International Inc. Stable composition comprising particles in a frozen aqueous matrix
WO2003082301A1 (en) * 2002-03-29 2003-10-09 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US4861869A (en) 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
KR960001742B1 (en) 1986-12-30 1996-02-05 Nihon Medi Physics K K High molecular compound comprising unit of asialoglycoprotein
US4965392A (en) 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5116599A (en) 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
WO1991016076A1 (en) 1990-04-17 1991-10-31 Mallinckrodt Medical, Inc. Method and kit for preparing technetium-99m complexes
JPH06501450A (ja) * 1990-06-01 1994-02-17 インスティトゥート　フュア　ディアグノスティックフォルシュング　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング　アン　デア　フライエン　ウニヴェルジテート　ベルリン シクロペンタジエニルカルボニル―９９ｍＴｃ錯体、その製造法および診断学への該化合物の使用
DE69332952T2 (de) * 1992-09-04 2004-02-19 The General Hospital Corp., Boston Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere
US5605672A (en) 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5955053A (en) 1996-05-06 1999-09-21 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
US5986074A (en) 1996-05-06 1999-11-16 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
NZ507540A (en) * 1998-04-28 2002-07-26 Jagotec Ag Hyaluronic acid based imaging agents containing gadolinium or iron oxide
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6399951B1 (en) 2000-02-02 2002-06-04 Ut-Battelle, Llc Simultaneous CT and SPECT tomography using CZT detectors
CA2406852A1 (en) 2000-04-20 2001-11-01 The University Of British Columbia Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy
CA2427911A1 (en) 2000-11-03 2002-05-10 Bristol Myers Squibb Company Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
US6623721B2 (en) 2000-12-18 2003-09-23 Draximage, Inc. Bifunctional chelating compounds containing hydroxamic acid residues
GB0111204D0 (en) 2001-05-08 2001-06-27 Mertek Ltd High flux,high energy photon source
DE60335608D1 (de) 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
WO2003086474A2 (en) * 2002-04-11 2003-10-23 Carbomer, Inc Fluorinated or paramagnetic alginate polymer, annexin paramagnetic conjugate, and their use as contrasting agent in mri
US20040022729A1 (en) * 2002-07-31 2004-02-05 Uzgiris Egidijus E. Method for binding molecular agents to angiogencic blood vessels
US20040042959A1 (en) 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
KR101086690B1 (ko) 2002-11-07 2011-11-25 셀>포인트, 엘엘씨 에틸렌디시스테인（ｅｃ）－약물 콘쥬게이트, 조성물 및조직 특이적 질환 영상 방법
US20050024380A1 (en) 2003-07-28 2005-02-03 Lin Lin Method for reducing random access memory of IC in display devices
US7790141B2 (en) * 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
CN1969190A (zh) * 2004-04-20 2007-05-23 爱默蕾大学 多峰性纳米结构，其制造方法以及其使用方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003480A1 (en) * 1990-08-17 1992-03-05 Drug Delivery System Institute, Ltd. N-acetylcarboxymethylchitosan derivative and production thereof
JPH0597712A (ja) * 1991-10-04 1993-04-20 Nippon Mejifuijitsukusu Kk 診断用造影剤
WO1997025979A1 (en) * 1996-01-18 1997-07-24 Perio Products Ltd. Gastrointestinal drug delivery system
WO1999018938A1 (en) * 1997-10-09 1999-04-22 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
WO1999020316A1 (en) * 1997-10-20 1999-04-29 Board Of Regents, The University Of Texas System Single photon-emitting radiotraces and methods for their use
WO2000027889A1 (en) * 1998-11-10 2000-05-18 Netech Inc. Functional chitosan derivative
WO2002087498A2 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
WO2003035031A1 (en) * 2001-10-19 2003-05-01 Baxter International Inc. Stable composition comprising particles in a frozen aqueous matrix
WO2003082301A1 (en) * 2002-03-29 2003-10-09 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012011494; 薬剤学 Ｖｏｌ．５２（１）, 1992, ｐ．５９-６７ *
JPN6012011497; 糖化学の基礎 , 19950810, ｐ．１５１, 株式会社講談社 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011063572A (ja) * 2009-09-18 2011-03-31 Kyushu Univ 診断用造影剤
JP2014522808A (ja) * 2011-06-17 2014-09-08 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 二官能性ホスホネートキレート剤
JP2015512408A (ja) * 2012-03-26 2015-04-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 画像化および治療のためのエチレンジシステイン−糖接合体の効率的な合成
JP2022544836A (ja) * 2019-08-19 2022-10-21 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド Ｍ２マクロファージおよび骨髄系由来サプレッサー細胞を除去するための組成物ならびに関連する方法
JP2023553494A (ja) * 2020-12-28 2023-12-21 ボストン サイエンティフィック サイムド，インコーポレイテッド 改善された放射線造影特性を有する多糖

Also Published As

Publication number Publication date
NO20074025L (no) 2007-09-27
BRPI0606395A2 (pt) 2009-06-23
EP1846042A2 (en) 2007-10-24
IL184415A0 (en) 2008-12-29
US20060182687A1 (en) 2006-08-17
AU2006204045A1 (en) 2006-07-13
CA2593256A1 (en) 2006-07-13
US8147805B2 (en) 2012-04-03
AU2006204045B2 (en) 2010-10-14
AU2011200132B2 (en) 2012-10-11
AU2011200132A1 (en) 2011-02-03
CN101137398B (zh) 2012-07-04
US20120276005A1 (en) 2012-11-01
WO2006074272A2 (en) 2006-07-13
KR20070106711A (ko) 2007-11-05
WO2006074272A8 (en) 2006-12-28
WO2006074272A3 (en) 2007-05-31
CN101137398A (zh) 2008-03-05
KR101313712B1 (ko) 2013-10-01

Similar Documents

Publication Publication Date Title
KR101313712B1 (ko) 이중 영상화 및 방사선화학요법용 접합체: 조성물,제조방법 및 적용
US20260021211A1 (en) Dual mode radiotracer and -therapeutics
US20250057993A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
JP5781026B2 (ja) エチレンジシステイン（ｅｃ）−薬物結合体
CA2682064C (en) Compositions for targeted imaging and therapy
EP2079486B1 (en) Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US7067111B1 (en) Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
JP2008534617A (ja) キレート剤としてのポリ（ペプチド）：製造方法および用途
US11186598B2 (en) Radioactive phospholipid metal chelates for cancer imaging and therapy
JP2009534381A (ja) 細胞画像化および治療のための組成物および方法
CA2394959A1 (en) Labelled ascorbic acid derivatives
HK40022705B (en) Dual mode radiotracer and -therapeutics
HK40022705A (en) Dual mode radiotracer and -therapeutics
HK1132672A (en) Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
HK1132672B (en) Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120702

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121004